MyPeptideMatchOverview
Liraglutide is an FDA-approved GLP-1 receptor agonist sold as Victoza (type 2 diabetes) and Saxenda (chronic weight management). It was one of the first GLP-1 therapies to be widely used for weight loss and remains a standard option. Like semaglutide and tirzepatide, it works by mimicking gut hormones that regulate insulin and appetite. Liraglutide is given daily by injection, whereas semaglutide is typically once weekly—so choice often depends on preference, access, and cost. Evidence from the SCALE and LEADER trials supports its use for weight loss and cardiovascular outcomes.
How It Works (Mechanism of Action)
Liraglutide mimics GLP-1, increasing insulin release in response to meals, reducing glucagon, slowing gastric emptying, and reducing appetite via central effects. It has a half-life that allows once-daily dosing. The mechanism is the same class as semaglutide, with formulation and dosing frequency being the main differences.
Primary Uses
Weight Management
Saxenda is approved for chronic weight management in adults with obesity or overweight with comorbidity. In the SCALE trials, participants lost on average about 5–8% of body weight over 56 weeks with lifestyle intervention. It is effective though often somewhat less than once-weekly semaglutide in head-to-head comparisons.
